{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-24-000066","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.033496+00:00","generated_at":"2026-06-03T09:14:33.797722+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin Q1 revenue $649M (+9% YoY); raises non-GAAP EPS and margin guidance","bullets":["GAAP diluted EPS $0.46 (+70% YoY); Non-GAAP diluted EPS $0.71 (+18% YoY).","VOXZOGO revenue $153M (+74% YoY); over 3,100 children treated (+102% YoY).","Full-year 2024 total revenue reaffirmed; non-GAAP margin and EPS guidance raised on $35-40M net OpEx savings.","R&D portfolio prioritized: accelerated BMN 333, BMN 349, BMN 351; discontinued BMN 331, 255, 355, 365."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-24-000066","json":"https://secwatch.observer/filing/0001048477-24-000066.json","markdown":"https://secwatch.observer/filing/0001048477-24-000066.md","text":"https://secwatch.observer/filing/0001048477-24-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/0001048477-24-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/bmrn-20240424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T09:14:33.797722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e3650ad2d8fc5eddef70311253276108920a9b7","claim":"BIOMARIN PHARMACEUTICAL INC reported first quarter ended March 31, 2024 results: revenue $648.8 million, net income $88.7 million, EPS $0.46. Guidance reaffirmed.","evidence_excerpt":"Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Record Financial Results for the First Quarter 2024 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO ® Net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/0001048477-24-000066-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$648.8 million"},{"label":"Net income","value":"$88.7 million"},{"label":"EPS","value":"$0.46"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}